Menstrual Dysfunction in Girls from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study

Journal of Clinical Endocrinology and Metabolism

Volumn 103, Issue 6, 2018, Pages 2309-2318

  Kelsey, Megan M ^a   Braffett, Barbara H ^b   Geffner, Mitchell E ^c   Levitsky, Lynne L ^d   Caprio, Sonia ^e   McKay, Siripoom V ^f   Shah, Rachana ^g   Sprague, Jennifer E ^h   Arslanian, Silva A ⁱ  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ESTRADIOL; INSULIN; METFORMIN; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG DOSE TITRATION; ESTRADIOL BLOOD LEVEL; FEMALE; FREE ANDROGEN INDEX; GLYCEMIC CONTROL; HUMAN; HYPERANDROGENISM; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; INSULIN RESISTANCE; LIFESTYLE; MENSTRUATION DISORDER; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANDROGENS; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; MENSTRUATION DISTURBANCES; METFORMIN; ROSIGLITAZONE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 85048652625     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2018-00132     Document Type: Article

References (42)

1. Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA. The association of obesity with infertility and related menstural abnormalities in women. Int J Obes. 1979;3(1):57-73.
2. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68(5):209-217.
3. Blank SK, Helm KD, McCartney CR, Marshall JC. Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci. 2008;1135(1): 76-84.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800.
5. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347-363.
6. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62(5):904-910.
7. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988;67(3):460-464.
8. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138(1):38-44.
9. Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitlian G, Gibbs K, Polotsky HN, Feng S, Isaac B, Santoro N. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007;92(7):2468-2473.
10. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87(4):1555-1559.
11. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24): 2247-2256.
12. Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D; TODAY Study Group. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8(2):74-87.
13. Legro RS, Lin HM, Demers LM, Lloyd T. Rapid maturation of the reproductive axis during perimenarche independent of body composition. J Clin Endocrinol Metab. 2000;85(3):1021-1025.
14. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672.
15. George L, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab. 2011;96(7):2136-2145.
16. Uwaifo GI, Fallon EM, Chin J, Elberg J, Parikh SJ, Yanovski JA. Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children. Diabetes Care. 2002;25(11):2081-2087.
17. Sjaarda LG, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Oral disposition index in obese youth from normal to prediabetes to diabetes: relationship to clamp disposition index. J Pediatr. 2012;161(1):51-57.
18. Bui HN, Sluss PM, Hayes FJ, Blincko S, Knol DL, Blankenstein MA, Heijboer AC: Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clin Chim Acta. 2015;450:227-232.
19. Rieder J, Santoro N, Cohen HW, Marantz P, Coupey SM. Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. J Adolesc Health. 2008;43(2):115-124.
20. Treloar AE, Behn BG, Cowan DW. Analysis of gestational interval. Am J Obstet Gynecol. 1967;99(1):34-45.
21. Vollman RF. The menstrual cycle. Major Probl Obstet Gynecol. 1977;7:1-193.
22. Radivojević T, Anselmi J, Scalas E. Ergodic transition in a simple model of the continuous double auction. PLoS One. 2014;9(2): e88095.
23. Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt). 2011;20(4):533-538.
24. Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res. 2010;1364: 186-197.
25. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod. 2004;19(2):383-392.
26. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes. 2001;50(11):2444-2450.
27. Kelly LA, Lane CJ, Weigensberg MJ, Toledo-Corral CM, Goran MI. Pubertal changes of insulin sensitivity, acute insulin response, and β-cell function in overweight Latino youth. J Pediatr. 2011; 158(3):442-446.
28. Campbell SE, Febbraio MA. Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. Am J Physiol Endocrinol Metab. 2002;282(5):E1139-E1146.
29. Kumagai S, Holmäng A, Björntorp P. The effects of oestrogen and progesterone on insulin sensitivity in female rats. Acta Physiol Scand. 1993;149(1):91-97.
30. Cucinelli F, Paparella P, Soranna L, Barini A, Cinque B, Mancuso S, Lanzone A. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol. 1999;140(3):215-223.
31. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, Bush TL. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care. 1998;21(10):1589-1595.
32. Evans EM, Van Pelt RE, Binder EF, Williams DB, Ehsani AA, Kohrt WM. Effects of HRT and exercise training on insulin action, glucose tolerance, and body composition in older women. J Appl Physiol (1985). 2001;90(6):2033-2040.
33. Jensen MD, Martin ML, Cryer PE, Roust LR. Effects of estrogen on free fatty acid metabolism in humans. Am J Physiol. 1994;266(6 Pt 1): E914-E920.
34. O'Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab. 1995;80(6):1783-1788.
35. Van Pelt RE, Gozansky WS, Schwartz RS, Kohrt WM. Intravenous estrogens increase insulin clearance and action in postmenopausal women. Am J Physiol Endocrinol Metab. 2003;285(2):E311-E317.
36. Escalante Pulido JM, Alpizar Salazar M. Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. Arch Med Res. 1999;30(1):19-22.
37. Mauvais-Jarvis F. Role of sex steroids in b cell function, growth, and survival. Trends Endocrinol Metab. 2016;27(12):844-855.
38. Ohman-Hanson RA, Cree-Green M, Kelsey MM, Bessesen DH, Sharp TA, Pyle L, Pereira RI, Nadeau KJ. Ethnic and sex differences in adiponectin: from childhood to adulthood. J Clin Endocrinol Metab. 2016;101(12):4808-4815.
39. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82(4): 893-902.
40. Liao L, Tian YJ, Zhao JJ, Xin Y, Xing HY, Dong JJ. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J (Engl). 2011;124(5):714-718.
41. Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfützner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2007;1(2): 211-217.
42. YilmazM, Biri A, Karakoç A, Törüner F, Bingöl B, Cakir N, Tiras B, Ayvaz G, Arslan M. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest. 2005;28(11):1003-1008.